




PHARMACEUTICAL 2019

Larimar Therapeutics Inc.
Rank 144 of 363





RealRate

PHARMACEUTICAL 2019

Larimar Therapeutics Inc.
Rank 144 of 363



The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 132%, being 95% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	121,330
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,306
Liabilities, Non-Current	0
Other Assets	57
Other Compr. Net Income	25
Other Expenses	0
Other Liabilities	15,185
Other Net Income	-246
Other Revenues	0
Property and Equipment	375
Research and Development	47,929
Selling, General and Administrative Expense	13,193

Output Variable	Value in 1000 USD
Assets	121,762
Liabilities	28,491
Expenses	61,122
Revenues	0
Stockholders Equity	93,271
Net Income	-61,368
Comprehensive Net Income	-61,356
Economic Capital Ratio	132%